Ozempic for Diabetes: Why It Was Prescribed Before the Hype

Ozempic was approved in December 2017 for one job: lowering blood sugar in adults with type 2 diabetes. That's still its main FDA-approved use. Since then it has also been approved to lower the risk of heart attack, stroke and kidney disease getting worse in people with type 2 diabetes, which is why many diabetes specialists now reach for it early rather than as a last resort. The weight-loss fame came later, and it's a side story to what the drug was built for.

If you have type 2 diabetes and your doctor has suggested Ozempic, here's what it actually does for blood sugar, what results to expect, how it fits with other diabetes medicines, and what to watch for.

According to its FDA label, Ozempic is approved for adults with type 2 diabetes to:

It's not approved for type 1 diabetes, and it isn't a substitute for insulin. Since May 2026 there's also a pill version, Ozempic tablets, which replaced Rybelsus in the U.S. for people who'd rather not inject.

Ozempic contains semaglutide, a long-acting copy of GLP-1, a gut hormone your body releases after meals. It lowers blood sugar in three ways at once: it helps the pancreas release more insulin when glucose is high, it reduces glucagon (a hormone that tells the liver to release sugar), and it slows how quickly food leaves the stomach, which blunts the spike after meals. It also reduces appetite, which helps with weight, and weight loss itself improves insulin resistance. For the hormone behind all this, see What Is GLP-1?.

The insulin boost is glucose-dependent, meaning it fades as blood sugar comes down. That's why Ozempic alone rarely causes dangerous lows. The risk rises when it's combined with insulin or sulfonylureas like glipizide or glimepiride.

In the SUSTAIN clinical trials, semaglutide typically lowered A1C by about 1.5 to 2 percentage points, depending on the dose and starting level. For someone starting at an A1C of 8.5%, that can mean landing near or under the common target of 7%. Many people also lost weight, though usually less than people without diabetes do on the same drug.

Two practical points. First, don't judge the drug by the first month; the 0.25 mg dose is for tolerance, not results. Second, A1C reflects about three months of blood sugar, so the first meaningful A1C check is usually around 12 weeks after starting. Your prescriber decides when and whether to increase the dose, based on your numbers and side effects.

Older diabetes drugs were judged almost entirely by how much they lowered A1C. Semaglutide changed that. In SUSTAIN-6, people with type 2 diabetes and high cardiovascular risk had 26% fewer major cardiovascular events on semaglutide than on placebo. In the FLOW trial, people with type 2 diabetes and chronic kidney disease had a 24% lower risk of serious kidney outcomes.

Because of results like these, the American Diabetes Association's Standards of Care recommend a GLP-1 drug or an SGLT2 inhibitor for people with type 2 diabetes who have heart disease or kidney disease, regardless of their A1C. In other words, for some patients, Ozempic is prescribed to protect organs, not just to bring a number down.

Many people end up on Ozempic plus metformin, sometimes with an SGLT2 inhibitor too. If you're comparing options for cost or coverage reasons, our Ozempic alternatives guide lays out the choices.

Nausea, diarrhea, vomiting and constipation are the most common side effects, especially during the first weeks and after each dose increase. Most people find they settle with time, smaller meals and staying hydrated. Beyond that, a few issues matter more for people with diabetes specifically:

For the full safety picture, including rare risks like pancreatitis and gallbladder problems, see Is Ozempic Safe?.

Ozempic isn't approved for prediabetes, and insurance rarely covers it for that. People with prediabetes and obesity may qualify for a weight-management GLP-1 such as Wegovy or Zepbound instead.

It also isn't approved for type 1 diabetes. Some specialists use GLP-1 drugs off-label alongside insulin in carefully selected type 1 patients, but it never replaces insulin, and it shouldn't be used that way without close supervision.

This is where having type 2 diabetes helps. Most commercial plans, Medicare Part D plans and Medicaid programs cover Ozempic for type 2 diabetes, often after prior authorization and sometimes after a trial of metformin. Medicare Part D caps total yearly out-of-pocket drug costs at $2,100 in 2026. Without coverage, Novo Nordisk's self-pay price is $349 a month for doses up to 1 mg. Our insurance guide explains how to check your plan and appeal a denial.

Type 2 diabetes is a long-term condition, and Ozempic works only while you take it. When people stop, A1C usually rises back toward where it was within a few months. That's why stopping should be planned with your doctor, ideally with a replacement treatment ready. See what happens when you stop Ozempic. If you miss a dose, the label says to take it within five days or skip it; our missed dose guide has the details.

Before Ozempic was a weight-loss headline, it was, and still is, a type 2 diabetes medicine with strong evidence behind it. It lowers A1C substantially, rarely causes lows on its own, helps with weight, and reduces heart and kidney risk in the people most likely to need that protection. Its downsides are mainly stomach side effects early on and the need to keep taking it. For many people with type 2 diabetes, that's a trade worth making.